Paper18686
On the optimal dosage of Pro-Leu-Gly-NH2 (MIF) in neuropharmacological tests and clinical use.
Björkman S and 1 other. Naunyn Schmiedebergs Arch Pharmacol, 1977. Cited by 28 papers, by iCite.
Cite this record
ConductScience Library. On the optimal dosage of Pro-Leu-Gly-NH2 (MIF) in neuropharmacological tests and clinical use. Papers, record 18686. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/18686
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- On the optimal dosage of Pro-Leu-Gly-NH2 (MIF) in neuropharmacological tests and clinical use.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| MSH Release-Inhibiting Hormone | Major topic |
| Oxotremorine | Major topic |
| Tremor | Major topic |
| Animals | |
| Dose-Response Relationship, Drug | |
| Male | |
| Mice |
Source PubMed
References15
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 4633626 | Deserpidine antagonism by a tripeptide, L-prolyl-L-leucyglycinamide. | Neuroendocrinology | 1973 | https://conductscience.org/library/papers/4633626 | PubMed |
| 2 | 4212370 | Studies on the inhibition of oxotremorine induced tremor by a melanocyte-stimulating hormone release-inhibiting factor, thyrotropin releasing hormone and related peptides. | FEBS Lett | 1974 | https://conductscience.org/library/papers/4212370 | PubMed |
| 3 | 4947365 | DOPA potentiation by a hypothalamic factor, MSH release-inhibiting hormone (MIF). | Life Sci I | 1971 | https://conductscience.org/library/papers/4947365 | PubMed |
| 4 | 238221 | Intensification of central catecholaminergin and serotonergic processes by the hypothalamic factors MIF and TRF and by angiotensin II. | Pharmacol Biochem Behav | 1975 | https://conductscience.org/library/papers/238221 | PubMed |
| 5 | 5815 | [Infusion therapy with mif (melanocyte inhibiting factor) in Parkinson's disease (author's transl)]. | Wien Klin Wochenschr | 1975 | https://conductscience.org/library/papers/5815 | PubMed |
| 6 | 4640811 | Preliminary clinical studies with L-prolyl-L-leucyl-glycine amide in Parkinson's disease. | Can Med Assoc J | 1972 | https://conductscience.org/library/papers/4640811 | PubMed |
| 7 | 3279 | Double-blind evaluation of oral L-prolyl-Lleucyl-glycine amide in Parkinson's disease. | Can Med Assoc J | 1976 | https://conductscience.org/library/papers/3279 | PubMed |
| 8 | 5064701 | Oxotremorine antagonism by a hypothalamic hormone, melanocyte-stimulating hormone release-inhibiting factor (MIF). | Proc Soc Exp Biol Med | 1972 | https://conductscience.org/library/papers/5064701 | PubMed |
| 9 | 11638 | Peptides related to melanostatin (Pro-Leu-Gly-NH2) as inhibitors of oxotremorine-induced tremor. | Acta Pharm Suec | 1976 | https://conductscience.org/library/papers/11638 | PubMed |
| 10 | 4614981 | Effect of melanocyte-stimulating hormone-release inhibiting factor (MIF) in Parkinson's syndrom. | Eur Neurol | 1974 | https://conductscience.org/library/papers/4614981 | PubMed |
| 11 | 4746492 | Dopamine synthesis: stimulation by a hypothalamic factor. | Science | 1973 | https://conductscience.org/library/papers/4746492 | PubMed |
| 12 | 4858836 | DOPA potentiation in ablated animals and brain levels of biogenic amines in intact animals after prolyl-leucylglycinamide. | Neuroendocrinology | 1974 | https://conductscience.org/library/papers/4858836 | PubMed |
| 13 | 7268 | Commentary: Neuropharmacology of hypothalamic releasing factors. | Biochem Pharmacol | 1976 | https://conductscience.org/library/papers/7268 | PubMed |
| 14 | 4815 | Alpha-MSH and MIF-I effects on catecholamine levels and synthesis in various rat brain areas. | Pharmacol Biochem Behav | 1975 | https://conductscience.org/library/papers/4815 | PubMed |
| 15 | 4837910 | Oxotremorine antagonism by prolyl-leucyl-glycine-amide administered by different routes and with several anticholinergics. | Pharmacol Biochem Behav | 1974 | https://conductscience.org/library/papers/4837910 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 38116429 | Stapling Amantadine to Melanostatin Neuropeptide: Discovery of Potent Positive Allosteric Modulators of the D2 Receptors. | ACS Med Chem Lett | 2023 | https://conductscience.org/library/papers/38116429 | PubMed |
| 33704752 | Lambda Red-Mediated Recombination in Shiga Toxin-Producing Escherichia coli. | Methods Mol Biol | 2021 | https://conductscience.org/library/papers/33704752 | PubMed |
| 207560 | Behavioural effects of naloxone in rats. | Experientia | 1978 | https://conductscience.org/library/papers/207560 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| MIF | 4282 | PubTator's text mining | https://conductscience.org/library/genes/4282 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/18686
GET https://conductscience.org/api/papers/v1/18686/authors